Truist Securities Initiates Coverage On Apogee Therapeutics with Hold Rating, Announces Price Target of $83

Truist Securities analyst Danielle Brill initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Hold rating and announces Price Target of $83.